Skip to content

Passive Smoking and LL-37 in Children

Salivary LL-37 and Periodontal Health in Children Exposed to Passive Smoking

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03639376
Enrollment
180
Registered
2018-08-21
Start date
2016-11-30
Completion date
2018-06-30
Last updated
2018-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Innate Immunity, Periodontal Health

Keywords

Children, Cotinine, LL-37, Passive smoking, Periodontal health, Saliva

Brief summary

This study investigates the salivary LL-37 in passive smoking-exposed and unexposed children and the association between salivary LL-37 levels and periodontal clinical parameters in these children.Unstimulated salivary samples were collected from 180 children (90 passive smoking-exposed and 90 passive smoking-unexposed)

Detailed description

Diverse mechanisms conduce to the detrimental periodontal effects of passive smoking, including alteration of both microbial and host response factors. Antimicrobial peptides are considered to be an important intermediate step in initiating an initial immune response against the microbial side of the oral gingival epithelium and in the transition to acquired immunity. LL-37 has a wide antimicrobial activity against both cariogenic and periopathogenic bacteria and its role in maintaining oral health has recently been stated

Interventions

None listed

Sponsors

Kırıkkale University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
6 Years to 12 Years
Healthy volunteers
Yes

Inclusion criteria

* Systemically healthy children

Exclusion criteria

* Any medications known to affect defense system and periodontium * The presence of orthodontic / intraoral appliance

Design outcomes

Primary

MeasureTime frameDescription
Antimicrobial PeptideIn the first 18 months of studyLL-37 (pg/mL)

Secondary

MeasureTime frameDescription
Passive smoking measurementIn the first 18 months of studyCotinine (ng/mL)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026